TLP
IMGN

Tri Locum Partners’s Immunogen Inc IMGN Stock Holding History

Tri Locum Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-369,912
Closed -$5.87M – 66
2023
Q3 		$5.87M Buy
369,912
+72,105
+24% +$1.2M 1.88% 17
2023
Q2 		$5.62M Buy
+297,807
New +$3.52M 2.09% 20

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Tri Locum Partners's IMGN Position: Q4 2023 in Review

Tri Locum Partners sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 369,912 shares — an estimated $5.87M sold.

Tri Locum Partners first reported a position in IMGN in Q2 2023 and held it in 2 quarters. The position peaked at $5.87M in Q3 2023. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • Tri Locum Partners reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 369,912 Immunogen Inc shares in Q4 2023, an estimated $5.87M.
  • Tri Locum Partners first reported a position in Immunogen Inc in Q2 2023 and held it in 2 quarters.
  • Tri Locum Partners's Immunogen Inc position peaked at $5.87M in Q3 2023.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.